BDRX Biodexa Pharmaceuticals PLC

 

Filed pursuant to Rule 424(b)(3)

Registration No.: 333-270353

 

PROSPECTUS SUPPLEMENT No. 16

(To the Prospectus dated May 2, 2024)

 

BIODEXA PHARMACEUTICALS PLC

 

8,203,200 Ordinary Shares Representing 20,508 American Depositary Shares

 

This prospectus supplement No. 16 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 3 to Registration Statement on Form F-1, effective as of May 2, 2024 (the “Prospectus”), related to the resale by the selling shareholders identified in the Prospectus of up to an aggregate of 8,203,200 of our ordinary shares, nominal value £0.001 per share, represented by 20,508 American Depositary Shares (the “Depositary Shares”).

 

This Prospectus Supplement is being filed in order to incorporate into and include in the Prospectus the information contained in our attached Form 6-K, filed with the Securities and Exchange Commission on November 1, 2024.

 

This Prospectus Supplement should be read in conjunction with the Prospectus and is qualified by reference to the Prospectus except to the extent that the information in this Prospectus Supplement supersedes the information contained therein.

 

Our Depositary Shares are listed on the NASDAQ Capital Market under the symbol “BDRX.” The last reported closing price of Depositary Shares on the NASDAQ Capital Market on November 1, 2024 was $5.91.

 

Investing in our securities involves risks. See “Risk Factors” beginning on page 11 of the Prospectus and in the documents incorporated by reference in the Prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

______________________________

 

The date of this Prospectus Supplement is November 4, 2024.

 

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2024

Commission File Number 001-37652

 

Biodexa Pharmaceuticals PLC

(Translation of registrant’s name into English)

 

1 Caspian Point,

Caspian Way

Cardiff, CF10 4DQ, United Kingdom

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F x      Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

EXPLANATORY NOTE

 

Biodexa Pharmaceuticals plc (the “Company”) is furnishing this Report on Form 6-K to report on the appointment of PKF Littlejohn LLP as its independent registered public accounting firm, with an effective date of October 31, 2024, and the resignation of Forvis Mazars LLP (formerly known as Mazars LLP) as the Company’s independent registered public accounting firm with effect from October 25, 2024.

 

The change in auditors was made following notice from Forvis Mazars LLP of their intent to resign and a subsequent tender process. Both the commercial terms and expertise of the tender participants were assessed during the tender process. As a result of this process, the Audit Committee of the Board of Directors and the Board selected and, following the resignation of Forvis Mazars LLP, approved the appointment of PKF Littlejohn LLP as our independent registered public accounting firm. During the Company’s fiscal years ended December 31, 2022 and 2023, and through October 30, 2024, neither the Company, nor anyone acting on its behalf, consulted with PKF Littlejohn LLP regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and no written report or oral advice was provided that PKF Littlejohn LLP concluded was an important factor considered by the Company in reaching a decision as to any such accounting, auditing or financial reporting issue, or (ii) any matter that was the subject of a disagreement (as defined in Item 16F(a)(1)(iv) of Form 20-F and the related instructions) or a reportable event (as described in Item 16F(a)(1)(v) of Form 20-F).

 

The reports of Forvis Mazars LLP on our consolidated financial statements for the fiscal years ended December 31, 2022 and 2023 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principle, except that the audit report for the years ended December 31, 2022 and 2023 contained a modification regarding the Company’s ability to continue as a going concern.

 

During the two fiscal years ended December 31, 2022 and 2023 and the subsequent interim period through October 25, 2024, there were no disagreements, as that term is defined in Item 16F(a)(1)(iv) of Form 20-F, with Forvis Mazars LLP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Forvis Mazars LLP, would have caused Forvis Mazars LLP to make reference thereto in their reports on our consolidated financial statements for such fiscal years.

 

During the two fiscal years ended December 31, 2022 and 2023 and the subsequent interim period through October 25, 2024, there were no “reportable events” as that term is defined in Item 16F(a)(1)(v) of Form 20-F.

 

The Company provided Forvis Mazars LLP with a copy of the disclosures it is making in this Report on Form 6-K and requested that Forvis Mazars LLP furnish it with a letter addressed to the U.S. Securities and Exchange Commission (“SEC”) stating whether or not it agrees with the above disclosures and, if not, stating the respects in which it does not agree. A copy of Forvis Mazars LLP’s letter to the SEC, dated November 1, 2024, is attached as Exhibit 16.1 to this Report on Form 6-K.

 

The Company intends to use this Report on Form 6-K and the accompanying exhibit to satisfy its reporting obligations under Item 16F(a) of its Form 20-F for the year ending December 31, 2024, to the extent provided in and permitted by Paragraph 2 of the instructions to Item 16F of Form 20-F and plans to incorporate this Report on Form 6-K by reference into its Form 20-F to the extent necessary to satisfy such reporting obligations.

 

The information included in this Report on Form 6-K, including Exhibit 16.1, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Number 333-209365) and Form F-3 (File Number 333-267932) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished. 

 

 

SUBMITTED HEREWITH

 

Attached to the Registrant’s Form 6-K filing for the month of October 2024 is:

 

Exhibit No.		Description
16.1		Forvis Mazars LLP Letter dated November 1, 2024.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Biodexa Pharmaceuticals PLC
Date: November 1, 2024	By:	/s/ Stephen Stamp
		Stephen Stamp
		Chief Executive Officer and Chief Financial Officer

 

 

Exhibit 16.1

 

30 Old Bailey London EC4M 7AU Tel: +44 (0)20 7063 4000 forvismazars.com/uk

 

 

 

Private & Confidential
Securities and Exchange Commission 100 F Street NE Washington D.C. 20549 United States of America
	Date:	1 November 2024

 

 

Ladies and Gentlemen,

 

We have been furnished with a copy of the form 6-K to be filed by our former client, Biodexa Pharmaceuticals plc, to satisfy its reporting obligations under Item 16F(a) of its Form 20-F for the year ending December 31, 2024.

 

We agree with the statements made in the form 6-K in response to that Item insofar as they relate to our Firm.

 

 

 

/s/ Forvis Mazars LLP

 

 

Forvis Mazars LLP

London

 

 

Forvis Mazars LLP
Forvis Mazars LLP is the UK firm of Forvis Mazars Group, a leading global professional services network. Forvis Mazars LLP is a limited liability partnership registered in England and Wales with registered number OC308299 and with its registered office at 30 Old Bailey, London, EC4M 7AU. Registered to carry on audit work in the UK by the Institute of Chartered Accountants in England and Wales. Details about our audit registration can be viewed at www.auditregister.org.uk under reference number C001139861. VAT number: GB 839 8356 73

 

 

 

 

 

---